| First Author | Niu T | Year | 2023 |
| Journal | Cell Commun Signal | Volume | 21 |
| Issue | 1 | Pages | 233 |
| PubMed ID | 37723552 | Mgi Jnum | J:340745 |
| Mgi Id | MGI:7530077 | Doi | 10.1186/s12964-023-01238-6 |
| Citation | Niu T, et al. (2023) LFA-1 knockout inhibited the tumor growth and is correlated with treg cells. Cell Commun Signal 21(1):233 |
| abstractText | Cancer immunotherapy has been proven to be clinically effective in multiple types of cancers. Lymphocyte function-associated antigen 1 (LFA-1), a member of the integrin family of adhesion molecules, is expressed mainly on alphabeta T cells. LFA-1 is associated with tumor immune responses, but its exact mechanism remains unknown. Here, two kinds of mice tumor model of LFA-1 knockout (LFA-1(-/-)) mice bearing subcutaneous tumor and Apc (Min/+);LFA-1(-/-) mice were used to confirm that LFA-1 knockout resulted in inhibition of tumor growth. Furthermore, it also demonstrated that the numbers of regulatory T cells (Treg cells) in the spleen, blood, mesenteric lymph nodes were decreased in LFA-1(-/-) mice, and the numbers of Treg cells in mesenteric lymph nodes were also decreased in Apc (Min/+);LFA-1(-/-) mice compared with Apc (Min/+) mice. LFA-1 inhibitor (BIRT377) was administered to subcutaneous tumor-bearing LFA-1(+/+) mice, and the results showed that the tumor growth was inhibited and the number of Treg cells was reduced. The analysis of TIMER tumor database indicated that LFA-1 expression is positively associated with Treg cells and TNM stage. Conclusively, this suggests that LFA-1 knockout would inhibit tumor growth and is correlated with Treg cells. LFA-1 may be one potential target for cancer immunotherapy. Video Abstract. |
